Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.

Circulation. Cardiovascular genetics - 1 Aug 2013

DeGorter Marianne K, Tirona Rommel G, Schwarz Ute I, Choi Yun-Hee, Dresser George K, Suskin Neville, Myers Kathryn, Zou GuangYong, Iwuchukwu Otito, Wei Wei-Qi, Wilke Russell A, Hegele Robert A, Kim Richard B

Abstract excerpt

BACKGROUND: A barrier to statin therapy is myopathy associated with elevated systemic drug exposure. Our objective was to examine the association between clinical and pharmacogenetic variables and statin concentrations in patients. METHODS AND RESULTS: In total, 299 patients taking atorvastatin o...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heptanoic Acids

Share to Hydroxycholesterols

Share to Liver-Specific Organic Anion Transporter 1

Share to Organic Anion Transporters

Share to Pyrroles

Share to Rosuvastatin Calcium

Source

Open in PubMed Open full text

Identifiers

PMID: 23876492
DOI: 10.1161/CIRCGENETICS.113.000099
PMCID: PMC3922121

Genes

ABCG2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23876492-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.PMID 23876492Read ↗

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.Semantic proximity Read ↗

Genetic Polymorphisms in Drug Transporter Genes (ABCB1, OATP1B1) and Their Impact on Statin Pharmacokinetics and Myopathy RiskSemantic proximity Read ↗

Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE's multiethnic population.Semantic proximity Read ↗

Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.Semantic proximity Read ↗

Comparative Analysis of Atorvastatin and Rosuvastatin Side Events and Risk Factors in the UAE Multiethnic Population: Focus on Pharmacogenomic VariantsSemantic proximity Read ↗

Pharmacogenomics of statin therapy: any new insights in efficacy or safety?Semantic proximity Read ↗

Clinical implications of pharmacogenetic variation on the effects of statins.Semantic proximity Read ↗

Genetic Determinants of Statin-induced Myopathy: A Network Meta-analysis of Observational Studies.Semantic proximity Read ↗

Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.Semantic proximity Read ↗

SLCO1B1 Polymorphisms and Statin-Induced MyopathySemantic proximity Read ↗

Pharmacogenomics, lipid disorders, and treatment options.Semantic proximity Read ↗

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin BioavailabilitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.